Singapore, Aug 9, 2010: Avexa Limited, a Melbourne-based biotechnology company with a focus on research and development of anti-infectives, has announced the appointment of Mr Iain Kirkwood to the Avexa Board as a Non-Executive Director. Mr Kirkwood’s appointment reaffirms the Board’s commitment to building a strong and dynamic team. This appointment will serve Avexa well, as it embarks on an independent review of the company’s current programmes designed to preserve and enhance shareholder value.

 

Mr Kirkwood brings extensive operational, financial and general management experience, particularly in the life sciences industry. He has vast boardroom experience currently serving as a Non-Executive Director on the Boards of Medical Developments International Ltd., Vision Group Ltd. and Broadvector Ltd, a private life sciences company.

 

He was a seed investor in start-up companies Bluechip Ltd. and Celvis Ltd, both of which have subsequently become public and unlisted. He continues to serve on the Board of both companies, and has played an active role in the development of their unique products for use in the life science and medical sector.

 

During his career, Mr Kirkwood has worked with a number of ASX listed companies, in senior management roles, including Woodside Petroleum Ltd. and Santos Ltd, and was previously the CFO of F.H. Faulding & Co. Ltd. and CEO of EpiTan Ltd. (now Clinuvel Pharmaceuticals Ltd).

 

Mr Joe Baini, Chairman of Avexa welcomed the appointment. “I’m delighted to welcome a person with Iain’s skills and commercial acumen. Iain’s vast industry experience coupled with his strong background in financial and general management, strengthens and complements the expertise of the existing Avexa Board,” Mr Baini said.